Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 1/20 | 0.45 |
| ▸ | PPARA | Q07869 | 1/20 | 0.45 |
| ▸ | FFAR4 | Q5NUL3 | 5/20 | 0.44 |
| ▸ | DGAT1 | O75907 | 6/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.40 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.40 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15420322 | 0.88 | GRM5 (0.41) | DGAT1MCHR1 | |
| SCHEMBL15420648 | 0.86 | DGAT1 (0.39) | FFAR4DGAT1MCHR1KCNH2 | |
| SCHEMBL12989748 | 0.86 | DGAT1 (0.39) | FFAR4DGAT1MCHR1KCNH2 | |
| SCHEMBL12989747 | 0.86 | DGAT1 (0.39) | FFAR4DGAT1MCHR1KCNH2 | |
| SCHEMBL15420543 | 0.85 | KDM4E (0.42) | DGAT1SCN9AKCNH2 | |
| SCHEMBL15441147 | 0.84 | PPARD (0.41) | PPARDPPARAFFAR4SCN9AMCHR1 | |
| SCHEMBL15420219 | 0.84 | PPARD (0.41) | PPARDPPARAFFAR4SCN9AMCHR1 | |
| SCHEMBL12987769 | 0.84 | PPARD (0.41) | PPARDPPARAFFAR4SCN9AMCHR1 | |
| SCHEMBL15441150 | 0.84 | PPARD (0.41) | PPARDPPARAFFAR4SCN9AMCHR1 | |
| SCHEMBL15420612 | 0.81 | GCGR (0.44) | FFAR4SCN8A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2694472-B1 | SULFONAMIDE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2020-03-11 | — | — | EP | disclosed |
| US-9527807-B2 | Sulfonamide derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-12-27 | — | — | US | disclosed |
| US-20140024650-A1 | SULFONAMIDE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140024650-A1 | SULFONAMIDE DERIVATIVE AND USE THEREOF | GRIN2A, GRIN2B, SLC1A2 | PPARD 215/4885PPARA 211/4885FFAR4 277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.